• IMPDH Inhibition Impairs PEDV Replication via Nucleotide Dis

  2026-06-06

  This study reveals that porcine epidemic diarrhea virus (PEDV) reprograms host guanine nucleotide biosynthesis by hijacking IMPDH activity to facilitate its replication. Both genetic and pharmacological inhibition of IMPDH, including with Merimepodib (VX-497), suppresses PEDV proliferation, highlighting a host-directed antiviral strategy with broad research implications.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-05

  This dissertation redefines how in vitro anti-cancer drug responses are measured, distinguishing between growth inhibition and cell death using separate viability metrics. By clarifying these mechanisms, the work provides a more nuanced framework for evaluating targeted agents like BCL-2 protein inhibitors in preclinical studies.

• Dimethyloxalylglycine (DMOG): Technical Parameters & Workflo

  2026-06-05

  Dimethyloxalylglycine (DMOG) enables controlled stabilization of hypoxia-inducible factors (HIF) for modeling hypoxic signaling and immune modulation in research studies. It is not suitable for diagnostic or clinical use and requires strict adherence to solubility and storage guidance for reliable results.

• Sulfo-NHS-LC-Biotin: Technical Guide for Protein Biotinylati

  2026-06-04

  Sulfo-NHS-LC-Biotin provides a water-soluble, membrane-impermeable solution for covalent biotinylation of primary amines, primarily on cell surface proteins. It addresses workflows that require stable, extracellular biotin tagging for detection or purification, but is not suited for reversible or intracellular biotinylation.

• Alistipes indistinctus Safeguards Gut Barrier Against LPS In

  2026-06-04

  A recent study demonstrates that Alistipes indistinctus, a gut commensal, exhibits probiotic-like properties by protecting intestinal barrier integrity against lipopolysaccharide-induced injury in vitro and in vivo. The findings provide mechanistic insight into its adhesion, survival, and anti-inflammatory effects, highlighting its potential as a next-generation probiotic for metabolic and inflammatory disease management.

• AICAR and AMPK: From Mechanistic Insight to Translational Im

  2026-06-03

  This article explores the transformative potential of AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside), a cell-permeable AMPK activator, in bridging the gap between metabolic mechanism and translational strategy. Drawing on the latest evidence for AMPK’s regulatory role in macrophage polarization and inflammation, we outline how researchers can leverage APExBIO’s AICAR to drive innovation in metabolic disease and immune modulation studies. Key protocol guidance, competitive benchmarking, and a forward-looking outlook position this piece as an essential read for translational scientists seeking credible, actionable insights.

• CD40-STING-TRAF2 Competition Drives IRF4+ B Cell Activation

  2026-06-03

  This study reveals that tertiary lymphoid structures (TLS) enriched in IRF4+ B cells predict improved survival in esophageal squamous cell carcinoma (ESCC). Mechanistically, the work uncovers how competitive binding of CD40 and STING to TRAF2 regulates IRF4-mediated B cell activation via non-canonical NF-κB signaling, informing new biomarker and therapeutic strategies.

• Viral Inducers of RIPK3 Degradation Control Necroptosis and

  2026-06-02

  This study uncovers how a class of orthopoxvirus proteins, termed viral inducers of RIPK3 degradation (vIRD), actively degrade the necroptosis adaptor RIPK3, thereby modulating virus-induced inflammation and replication. These findings reveal a sophisticated viral strategy to evade host cell death pathways, offering new perspectives for the study of innate immunity and host-pathogen evolution.

• BCECF-AM: Reliable Intracellular pH Measurement for Live-Cel

  2026-06-02

  BCECF-AM (SKU B5370) delivers reproducible, ratiometric intracellular pH measurement, supporting robust live-cell assays across mammalian, plant, and microbial systems. This article addresses real-world laboratory challenges, highlighting how this cell-permeable fluorescent probe—supplied by APExBIO—enables sensitive, validated analysis of cell viability, cytotoxicity, and protein secretion workflows.

• Gene Expression Profiling Reveals HR Repair Defects in Mesot

  2026-06-01

  Borchert et al. (2019) demonstrate that defects in homologous recombination repair (HRR), defined as 'BRCAness', are prevalent in malignant pleural mesothelioma (MPM) and predict susceptibility to PARP inhibition. Their expression-based classification offers a new approach to stratifying patients and informs therapeutic strategies beyond standard pemetrexed-based chemotherapy.

• Imidazoline Antagonists Boost Insulin via K+ Channel Inhibit

  2026-06-01

  This study demonstrates that imidazoline antagonists of α2-adrenoceptors increase insulin secretion in vitro by directly inhibiting ATP-sensitive potassium channels in pancreatic β-cells, rather than solely via adrenergic blockade. These findings refine our mechanistic understanding of insulinotropic drug action and inform pharmacological approaches for dissecting β-cell ion channel function.

• miR-18a/ALOXE3 Axis Regulates Ferroptosis in Glioblastoma

  2026-05-31

  This study uncovers how miR-18a directly targets and suppresses ALOXE3, reducing ferroptotic and anti-migration activity in glioblastoma. The findings reveal a new regulatory pathway in tumor progression and suggest the miR-18a/ALOXE3 axis as a candidate for therapeutic intervention.

• NF 449: Redefining Platelet P2X1 Antagonism in Thrombosis Re

  2026-05-30

  This article explores the mechanistic, experimental, and translational frontiers enabled by NF 449—a highly selective purinergic receptor antagonist targeting the P2X1 ion channel. We synthesize cutting-edge evidence, competitive context, and practical guidance for translational researchers, bridging rigorous mechanistic insight with strategic workflow recommendations. The discussion demonstrates how NF 449, available from APExBIO, empowers a new era of precision platelet aggregation inhibitor studies and antithrombotic agent development.

• (-)-Arctigenin: Targeting NF-κB Axis and TAMs for Cancer Res

  2026-05-29

  Explore how (-)-Arctigenin, a potent MEK1 inhibitor, uniquely disrupts NF-κB-driven tumor microenvironment signaling shaped by tumor-associated macrophages. This article delivers advanced insights on mechanistic targeting and translational assay design for oncology researchers.

• Adiponectin Alleviates Post-Splenectomy Cognitive Deficits v

  2026-05-29

  This study demonstrates that adiponectin administration before splenectomy in aged rats significantly reduces neuroinflammation and oxidative stress, thereby improving cognitive outcomes. The findings highlight the TLR4/MyD88/NF-κB pathway as a key mediator and suggest new avenues for perioperative neurocognitive disorder intervention.

458 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page